High expression of Lewisy/bantigens is associated with decreased survival in lymph node negative breast carcinomas

Breast Cancer Research

Volumn 7, Issue 5, 2005, Pages

  Madjd, Zahra ^a   Parsons, Tina ^b   Watson, Nicholas FS ^a   Spendlove, Ian ^a   Ellis, Ian ^c   Durrant, Lindy G ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Oxford Science Park   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; BLOOD GROUP ANTIGEN; FORMALDEHYDE; HAPTEN; LEWIS B ANTIGEN; LEWIS Y ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SC101; PARAFFIN; STREPTAVIDIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE NEGATIVE BREAST CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; NOTTINGHAM PROGNOSTIC INDICATOR; OVERALL SURVIVAL; PRIMARY TUMOR; SURVIVAL ANALYSIS; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR CELL; TUMOR CLASSIFICATION; UPREGULATION; BREAST TUMOR; CANCER INVASION; DNA MICROARRAY; GENETICS; LYMPH NODE METASTASIS; METHODOLOGY; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEWIS BLOOD-GROUP SYSTEM; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33644874643     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1305     Document Type: Article

References (26)

1. Wiley EL, Mendelsohn G, Eggleston JC: Distribution of carcinoembryonic antigens and blood group substances in adenocarcinoma of the colon. Lab Invest. 1981, 44: 507-513.
2. Inoue M, Nakayama M, Tanizawa O: Altered expression of Lewis blood group and related antigens in fetal, normal adult and malignant tissues of the uterine endometrium. Virchows Arch A Pathol Anat Histopathol. 1990, 416: 221-228 10.1007/BF01678981.
3. Inoue M, Sasagawa T, Saito J, Shimizu H, Ueda G, Tanizawa O, Nakayama M: Expression of blood group antigens A, B, H, Lewis-a, and Lewis-b in fetal, normal, and malignant tissues of the uterine endometrium. Cancer. 1987, 60: 2985-2993.
4. Dettke M, Palfi G, Loibner H: Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol. 2000, 68: 511-514.
5. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE: Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 1990, 50: 2183-2190.
6. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L, Das M: Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res. 1987, 47: 2531-2536.
7. Durrant LG, Singhal A, Jacobs E, Price MR: Development of second generation monoclonal antibodies recognising Lewisy/b antigen by anti-idiotypic immunisation. Hybridoma. 1993, 12: 647-660.
8. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410.
9. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW: Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992, 20: 479-489.
10. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW: Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994, 24: 41-47.
11. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987, 56: 489-492.
12. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992, 22: 207-219 10.1007/BF01840834.
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4: 844-847 10.1038/nm0798-844.
14. Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE: Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res. 2004, 10: 2797-2803.
15. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985, 109: 716-721.
16. Steplewska-Mazur K, Gabriel A, Zajecki W, Wylezol M, Gluck M: Breast cancer progression and expression of blood group-related tumor-associated antigens. Hybridoma. 2000, 19: 129-133 10.1089/02724570050031167.
17. Tauchi K, Kakudo K, Machimura T, Makuuchi H, Mitomi T: Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer. 1991, 67: 3042-3050.
18. Garrigues J, Anderson J, Hellstrom KE, Hellstrom I: Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes. J Cell Biol. 1994, 125: 129-142 10.1083/jcb.125.1.129.
19. Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V: Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res. 2004, 64: 1087-1093.
20. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004, 91: 1532-1542 10.1038/sj.bjc.6602184.
21. Flieger D, Hoff AS, Sauerbruch T, Schmidt-Wolf IG: Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression. Clin Exp Immunol. 2001, 123: 9-14 10.1046/j.1365-2249.2001.01435.x.
22. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W: Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999, 17: 478-484.
23. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, et al: Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000, 18: 2282-2292.
24. Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, et al: Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 2000, 60: 3254-3261.
25. Co MS, Baker J, Bednarik K, Janzek E, Neruda W, Mayer P, Plot R, Stumper B, Vasquez M, Queen C, et al: Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. Cancer Res. 1996, 56: 1118-1125.
26. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, Robertson JF, Ellis IO: Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology. 1995, 27: 219-226.